

September 10, 1971

Dr. Ralph Jacobsen  
Endo Laboratories  
Garden City, New York

Dear Ralph,

I am pleased to enclose the case summaries of nine subjects who received naloxone in oral doses above 200 mg/day, including subjects who received doses to 3,000 mg/day. We have requested the complete hematologic profiles obtained by Dr. Lerner and his staff, and these are included.

The present study program, using naloxone concentrate, is underway. Dr. Zaks has screened a number of applicants, and these are now in their periods of detoxification and medical examinations.

It was a pleasure to see you in Washington last week, and I look forward to the development of both EN 1639-A and naloxone pamoate, as both compounds seem to hold much promise for the eventual solution of the problem of opiate dependence, not only in our soldiers in Southeast Asia, but the many patients in our ghettos as well.

Thank you, again, for your support and enthusiasm.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry